In this work we studied the local anaesthetic activity of the essential oil obtained from Lavandula angustifolia Mill., a medicinal plant traditionally used as an antispasmodic. We compared its activity to the essential oils obtained from two citrus fruits, Citrus reticulata Blanco and Citrus limon (L.) Burm. f., which have no medical uses. Biological tests were also performed on the major pure components of L. angustifolia Mill. essential oil: linalol and linalyl acetate as determined by GC and confirmed by GC-MS. Anaesthetic activity was evaluated in vivo in the rabbit conjunctival reflex test, and in vitro in a rat phrenic nerve-hemidiaphragm preparation. The essential oil of L. angustifolia, linalyl acetate and linalol (0.01 - 10 μg/ml) but not the oils of Citrus reticulata and Citrus limon were able to drastically reduce, in a dose-dependent manner, the electrically evoked contractions of rat phrenic-hemidiaphragm. In the rabbit conjunctival reflex test treatment with a solution of essential oil of L. angustifolia, as well as linalyl acetate and linalol (30 - 2500 μg/ml administered in the conjunctival sac) allow a dose-dependent increase in the number of stimuli necessary to provoke the reflex, thus confirming in vivo the local anaesthetic activity observed in vitro .
Significance: Several endogenous molecules contribute to the building of a complex network of neural and hormonal signals that align food intake and energy expenditure. Cerebral histamine works as a satiety factor by activating histamine H 1 receptor (H 1 R) in specific hypothalamic nuclei. Indeed, atypical antipsychotics presumably cause obesity by targeting brain H 1 R. The endogenous lipid messenger oleoylethanolamide (OEA) mediates fat-induced satiety by engaging sensory fibers of the vagus nerve that project centrally. We find that depletion of brain histamine blunts OEA-induced hypophagia in mice. Our study uncovers previously unidentified neural signaling mechanisms involved in the anorectic action of OEA. Our data offer new perspectives for developing more effective and safer pharmacotherapies to treat obesity and ameliorate the profile of centrally acting drugs.